http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ADC Therapeutics SA (ADCT) to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
-
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
-
ADC Therapeutics SA (ADCT) Announces Voluntary Pause of Enrollment in Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
-
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Pa
-
ADC Therapeutics SA (ADCT) Announces Board Changes
-
ADC Therapeutics Announces Evolution of Board of Directors
-
ADC Therapeutics (ADCT) Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA in R/R DLBCL
-
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
-
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
-
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
-
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
-
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
-
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
-
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
-
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
-
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
-
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
-
ADC Therapeutics to Participate in February Investor Conferences
-
ADC Therapeutics SA (ADCT) Enters Development and License Option Agreement with IntoCell
-
IntoCell Enters into Development and License Option Agreement with ADC Therapeutics
-
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
-
ADC Therapeutics SA (ADCT) Appoints Mohamed Zaki as Chief Medical Officer
-
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
-
ADC Therapeutics (ADCT) and Sobi Granted EU Approval of ZYNLONTA
-
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
-
ADC Therapeutics SA (ADCT) Appoints Jose Carmona as CFO
-
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
-
FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS
-
Biocytogen Enters into Antibody Agreement with ADC Therapeutics (ADCT)
-
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
-
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
-
IGM Biosciences Inc. (IGMS) and ADC Therapeutics (ADCT) Announce Clinical Collaboration over Imvotamab (IGM-2323)
-
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgki
-
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgki
-
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgki
-
ADC Therapeutics SA (ADCT) Appoints Kristen Harrington-Smith as Chief Commercial Officer
-
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
-
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
-
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
-
ADC Therapeutics SA (ADCT) and Sobi Announce ZYNLONTA Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
-
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
-
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
-
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
-
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
-
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
-
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
-
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
-
ADC Therapeutics SA (ADCT) Doses First Patient in ZYNLONTA with Rituximab Phase 3 Trial
